Roche's Kadcyla set for EU launch, perhaps in Germany
This article was originally published in Scrip
Executive Summary
Roche is preparing to launch HER2 positive breast cancer antibody-drug conjugate Kadcyla (trastuzumab emtansine) in Europe following approval from the European Commission.
You may also be interested in...
Miniature By Design: Tarveda's Small Conjugates Could Be Better Fit For HSP90
Biotech's internally derived Pentarins offer the targeting advantages of antibody-drug conjugates in cancer, but with better affinity, pharmacokinetics and deeper tumor penetration.
WuXi eases CAR-T manufacturing burden with new US plant
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.
NICE lifts Entyvio restrictions after Takeda offers discount
Takeda has managed to persuade NICE, the health technology appraisal institute for England and Wales, to recommend its ulcerative colitis drug Entyvio (vedolizumab) without the restrictions the institute had previously stipulated – as long as the company offers a discount via a patient access scheme.